Jacques Cadranel

15.8k citations

241 papers · 7.6k indexed · 2 hit papers · h-index 44

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies

Papers in

Pulmonary and Respiratory Medicine 166
- Lung Cancer Treatments and Mutations 104
- Lung Cancer Diagnosis and Treatment 55
- Medical Imaging and Pathology Studies 28
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 28
Oncology 122
- Lung Cancer Research Studies 41
- Colorectal Cancer Treatments and Studies 24
- Cancer Immunotherapy and Biomarkers 21

Co-authors: Marie Wislez Martine Antoine Nathalie Rabbe B. Milleron Virginie Poulot C Mayaud Charles Mayaud Bruno Crestani
Journals: Lung Cancer (20 papers)Journal of Clinical Oncology (15 papers)Journal of Thoracic Oncology (14 papers)Annals of Oncology (14 papers)European Respiratory Journal (10 papers)
Partner nations: France United States United Kingdom

In The Last Decade

Jacques Cadranel

227 papers receiving 7.4k citations

Hit Papers

align trajectories log scale

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 2012 · 776 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 The Lancet Oncology
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by Jacques Cadranel

Since Specialization

Citations

This map shows the geographic impact of Jacques Cadranel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Cadranel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Cadranel more than expected).

Fields of papers citing papers by Jacques Cadranel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Cadranel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Cadranel. The network helps show where Jacques Cadranel may publish in the future.

Co-authors

The 25 scholars most cited alongside Jacques Cadranel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jacques Cadranel Line = papers co-authored together Jacques Cadranel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV : Results from the ANRS CO4 French hospital database on HIV International Journal of Cancer ·Sophie Grabar, 明子馬渕, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, 郭天彝, O. Lambotte, Romain Palich, 邦男丸山, Jean‐Philippe Spano, Anne‐Marie Bouvier, И.В. ТАТАРИНЦЕВА, Dominique Costagliola	2025	0
2	Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial Respiratory Medicine and Research ·Marion Ferreira, Théodora Bejan‐Angoulvant, S. Marchand‐Adam, Prajakta Dandekar, U. Gräwe, S. Jouneau, Hilario Nunès, David Montani, Cécile Chenivesse, Jacques Cadranel, Philippe Bonniaud, Bruno Crestani, Vincent Cottin, Agnès Caille	2024	1
3	ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. Journal of Clinical Oncology ·David Planchard, Nathalie Cozic, Marie Wislez, C. Chouaïd, Horacio Videla, Sophie Cousin, Céline Mascaux, Jacques Cadranel, Margaux Geier, Maria‐Rosa Ghigna, 나인형, Ricardo Zwirtes, Rachel Chiaverelli, Y.-J. Lee, Donal, Fernanda Mosele, Fabrice André, Guillaume Montagnac, Barbara Pistilli	2024	6
4	1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients Annals of Oncology ·Marc G. Denis, H. Sprankel, Christine Sagan, Matt Wenman, Audrey Vallée, Jacques Cadranel, Clarisse Audigier-Valette, Pascale Tomasini, Philippe Masson, 马醒华, 洋一杉田, Nicolas Girard, Alexis B. Cortot, Bridget Litts, I. Monnet, M. Marcq, T. Urban, Mao-Yun Lu, H. Léna, Jaafar Bennouna	2023	1
5	Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugués dans le cancer du sein : avis d’expert Bulletin du Cancer ·Luís Teixeira, Véronique Dièras, Bruno Crestani, Mathieu Léderlin, Cristian Villanueva, Boris Duchemann, Jean‐Yves Pierga, Jacques Cadranel	2023	2
6	585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib Annals of Oncology ·Tony Mok, Geoffrey Liu, Angelo M. Sykioco, 洋一杉田, Alexis B. Cortot, Dagan Zhang, R. Descourt, Mario Enrique Villarroel Lander, Parneet Cheema, 知哉松延, Eric N. Churchill, Seiji Kawaguchi, Ariele Silverio Cardoso, Ch.Manikanta, Kelly K. Chong, Zenghua Fan, Rebecca L. Merritt, Jacques Cadranel	2023	1
7	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study Cancers ·R. Descourt, M. Pérol, 李向前, David Planchard, B. Mennecier, Marie Wislez, Jacques Cadranel, Alexis B. Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schött, Éric Dansin, Jennifer Arrondeau, J.B. Auliac, Margaux Geier, C. Chouaïd	2022	5
8	Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer Pharmaceutics ·KE Shi-ta, Alicja Puszkiel, Ian Rocha de Almeida, Ekaterina Viktorovna Nekrasova, Céline Narjoz, Jennifer Arrondeau, Vincent Fallet, Nihel Khoudour, Monia Guidi, Michel Vidal, Xavier Declèves, Chantal Csajka, Jérôme Alexandre, Jacques Cadranel, Elizabeth Fabre, Marie Wislez, François Goldwasser, Benoı̂t Blanchet	2022	18
9	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients Cancers ·V. Gounant, M. Duruisseaux, George R. Plitnick, Judit Vikor, Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean‐Philippe Spano, Carole Hélissey, C. Chouaïd, Olivier Molinier, X. Dhalluin, Ludovic Doucet, J. Hureaux, Aurélie Cazes, Gérard Zalcman	2021	9
10	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy Cancers ·Katsunori Horikoshi, 憲士黒澤, Karen Leroy, I. Monnet, Solenn Brosseau, Nathalie Théou–Anton, Marie-Ange Massiani, S. Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux‐Leprieur, Jacques Cadranel, Marie Wislez	2021	14
11	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project Lung Cancer ·Hélène Blons, Nicole Bly, Jean‐Philippe Merlio, D. Debieuvre, Florence de Fraipont, Clarisse Audigier-Valette, Fabienne Escande, S. Hominal, Tracey Rose, Toro Felipe, L’Houcine Ouafik, Denis Moro‐Sibilot, Antoinette Lemoine, Alexandra Langlais, Jeanne Lima de Oliveira, Franck Morin, P.-J. Souquet, Fabrice Barlési, Jacques Cadranel, Michèle Beau‐Faller	2020	7
12	Are all ALK rearrangements created equal Translational Cancer Research ·M. Duruisseaux, 최승진, Denis Moro‐Sibilot, Jacques Cadranel	2017	1
13	Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers Lung Cancer ·M. Duruisseaux, Martine Antoine, Nathalie Rabbe, Anita Rodenas, 최승진, Roger Lacave, Virginie Poulot, Bélinda Duchêne, Isabelle Van Seuningen, Jacques Cadranel, Marie Wislez	2017	27
14	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma Lung Cancer ·V. Gounant, Solenn Brosseau, Charles Naltet, Santoso Sugondo, Martine Antoine, Claire Danel, Antoine Khalil, Jacques Cadranel, Gérard Zalcman	2016	31
15	The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase‐dependent mechanism International Journal of Cancer ·Vira Wardhana Istiantoro, Benoît Busser, Élisabeth Brambilla, Marie Wislez, Blaise Robin, Jacques Cadranel, Jean‐Luc Coll, Amandine Hurbin	2013	48
16	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 European Respiratory Journal ·Isabelle Borget, Jacques Cadranel, Jean‐Pierre Pignon, Élisabeth Quoix, Bruno Coudert, Virginie Westeel, Éric Dansin, J. Madelaine, Anne Madroszyk, S. Friard, Catherine Daniel, Franck Morin, C. Chouaïd, (unknown)	2011	27
17	Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations European Respiratory Journal ·Marie Wislez, Jacques Cadranel, Martine Antoine, B. Milleron, Marc Bazot, C Mayaud, M.-F. Carette	1999	69
18	Sarcoid-like Pulmonary Disorder in Human Immunodeficiency Virus–infected Patients Receiving Antiretroviral Therapy American Journal of Respiratory and Critical Care Medicine ·Jean‐Marc Naccache, Martine Antoine, Marie Wislez, Jocelyne Fleury‐Feith, Éric Oksenhendler, Charles Mayaud, Jacques Cadranel	1999	81
19	AIDS-related Primary Pulmonary Lymphoma American Journal of Respiratory and Critical Care Medicine ·Patrick Ray, Martine Antoine, Murielle Mary‐Krause, Marie-Gisèle Lebrette, Marie Wislez, Claudine Duvivier, Marie‐Caroline Meyohas, Pierre‐Marie Girard, Charles Mayaud, Jacques Cadranel	1998	37
20	Diagnosis of Smear-Negative Pulmonary Tuberculosis Using Sequence Capture Polymerase Chain Reaction American Journal of Respiratory and Critical Care Medicine ·Olivier Brugière, Martin Vokurka, Denise Lecossier, G. Mangiapan, Abdeltif Amrane, B. Milleron, C Mayaud, Jacques Cadranel, A J Hance	1997	27

About Jacques Cadranel

Jacques Cadranel is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Microbiology, Cancer Research and Epidemiology, having authored 241 papers that have together received 7.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (104 papers), Lung Cancer Diagnosis and Treatment (55 papers), Lung Cancer Research Studies (41 papers), Medical Imaging and Pathology Studies (28 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (28 papers), Colorectal Cancer Treatments and Studies (24 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Genomics and Diagnostics (18 papers). The work is most often cited by research in Oncology (3.6k citations), Pulmonary and Respiratory Medicine (4.2k citations), Immunology (1.3k citations), Pathology and Forensic Medicine (814 citations) and Microbiology (30 citations). Jacques Cadranel has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Marie Wislez, Martine Antoine, Nathalie Rabbe, B. Milleron, Martine Antoine, Virginie Poulot, C Mayaud, Charles Mayaud, Bruno Crestani and A. Lavolé. Their work appears in journals such as Lung Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology and European Respiratory Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact